TEL AVIV, Israel, June 3, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder ("ADHD"), is scheduled to ring the Opening Bell at the NASDAQ MarketSite in New York on Thursday, June 6, 2013, at 9:30 a.m. EDT to celebrate the Company's initial public offering on May 21st.
"We are honored to ring the Opening Bell at NASDAQ, one of the world's most prestigious stock exchanges, to celebrate the closing of our IPO," said Dr. Yaron Daniely, President & Chief Executive Officer of Alcobra. "With the capital we raised from our IPO we are able to move forward with our Phase III clinical trial for our proprietary drug, MG01CI, as a treatment for ADHD in adults, as well as studies for other indications."
Also, the Company has rescheduled its presentation at the Jefferies 2013 Global Healthcare Conference in New York. Dr. Daniely is now scheduled to present at 12:30 p.m. EDT on Thursday, June 6, 2013. The presentation will be broadcast over the Internet as a "live" listen only Webcast. To listen, please go to: http://www.alcobra-pharma.com/events.cfm. An archive of the event will also be available for those unable to listen live.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder. MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder in adults. The Company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information about Alcobra, please visit www.alcobra-pharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding our plans to move forward with Phase III clinical trials for MG01CI, as a treatment for ADHD in adults, as well as studies for other indications. These forward-looking statements, and their implications, involve certain risks and uncertainties, including, among others, risks impacting our ability to successfully conduct clinical trials to our product, other factors and risks that could cause the results to differ materially from those expected by our management as well as other risks and uncertainties, including those discussed in the "Risk Factors" section and elsewhere in our registration statement on Form F-1 filed with the SEC, which is available on the SEC's web site, www.sec.gov. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.
The content of websites or website links mentioned or provided herein is not part of this press release.
CONTACT: U.S. Investor Contacts: KCSA Strategic Communications Jeffrey Goldberger / Garth Russell +1 212.896.1249 / +1 212.896.1250 email@example.com / firstname.lastname@example.org Israel Investor Contact: Investor Relations Ltd. Moran Meir-Beres +011972-3-5167620 email@example.comSource:Alcobra Ltd.